SCHEMBL24596239

SCHEMBL24596239

FC(F)(F)c1ccc(Br)c(Nc2ccc(Cl)cc2)n1

nearest known ligand 0.42

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
NR1I2 O75469 1/20 0.42
AHR P35869 1/20 0.42
MAPT P10636 2/20 0.41
SMN1; SMN2 Q16637 2/20 0.41
TP53 P04637 1/20 0.41
POLB P06746 1/20 0.41
TRPA1 O75762 1/20 0.41
CDK1 P06493 1/20 0.39
MEN1 O00255 3/20 0.38
KMT2A Q03164 3/20 0.38
ALDH1A1 P00352 2/20 0.38
KDM4E B2RXH2 1/20 0.38
LMNA P02545 1/20 0.38
GLA P06280 1/20 0.38
L3MBTL1 Q9Y468 1/20 0.38
ALOX5 P09917 1/20 0.38
STK17A Q9UEE5 2/20 0.36
NPC1 O15118 1/20 0.36
GAA P10253 1/20 0.36
RAB9A P51151 1/20 0.36

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL24596389 0.82 IGF1R (0.48) MAPTCDK1MEN1KMT2AKDM4E
SCHEMBL24596403 0.82 KDM4E (0.47) SMN1; SMN2ALDH1A1KDM4ENPC1RAB9A
SCHEMBL24596272 0.81 CHEK1 (0.45) MAPTSMN1; SMN2CDK1MEN1KMT2A
SCHEMBL26631662 0.79 ROCK1 (0.42) MAPTSMN1; SMN2MEN1KMT2AALDH1A1
SCHEMBL26631718 0.78 MAPT (0.39) NR1I2AHRMAPTSMN1; SMN2TP53
SCHEMBL2529355 0.78 GPR119 (0.46) MAPTSMN1; SMN2TP53POLBTRPA1
SCHEMBL30049430 0.77 DHODH (0.55) SMN1; SMN2MEN1KMT2AALDH1A1LMNA
SCHEMBL27163628 0.77 DHODH (0.55) SMN1; SMN2MEN1KMT2AALDH1A1LMNA
SCHEMBL24596284 0.76 IGF1R (0.54) CDK1KMT2AKDM4EPDE5A
SCHEMBL24596185 0.76 ALOX15 (0.38) SMN1; SMN2TP53MEN1KMT2AKDM4E

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20240124454-A1 TRICYCLIC COMPOUND AND USE THEREOF NANJING ZAIMING PHARMACEUTICAL CO., LTD. (CN) 2024-04-18 US disclosed
EP-4273146-A1 TRICYCLIC COMPOUND AND USE THEREOF Nanjing Zaiming Pharmaceutical Co., Ltd. (CN) 2023-11-08 EP disclosed
EP-4273146-A1 TRICYCLIC COMPOUND AND USE THEREOF Nanjing Zaiming Pharmaceutical Co., Ltd. (CN) 2023-11-08 EP disclosed
CN-116670144-A Tricyclic compounds and uses thereof 南京再明医药有限公司 2023-08-29 CN disclosed
WO-2022143864-A1 TRICYCLIC COMPOUND AND USE THEREOF 江苏先声药业有限公司 2022-07-07 WO disclosed
WO-2022143864-A1 TRICYCLIC COMPOUND AND USE THEREOF 江苏先声药业有限公司 2022-07-07 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20240124454-A1 TRICYCLIC COMPOUND AND USE THEREOF MAT2A, MNAT1, KAT2A NR1I2 529/4885AHR 1989/4885MAPT 466/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.